3D Medicines Inc.

3D Medicines Inc. (3D Med) is a biopharmaceutical company focused on the research, development, and commercialization of innovative oncology drugs. Founded in 2014, the company is headquartered in Qingdao, China, with a vision to transform cancer into a chronic disease. 3D Medicines has a pipeline of 12 innovative drugs with differentiated clinical value, with 8 in clinical development or commercialization. Their lead product, Envafolimab, a subcutaneous injection PD-L1 antibody, has been approved for the treatment of microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company also has a robust pipeline of drugs, including 3D189 for multi-indication tumor, 3D229 for non-small cell lung cancer and other cancers, and others in various clinical stages. 3D Medicines aims to provide prolonged survival time and better quality of life for cancer patients.